CAR T-Cell Therapy at Massachusetts General Hospital

CAR T-Cell Therapy at Massachusetts General Hospital provides specialized cellular immunotherapy for selected patients with certain blood cancers and other eligible malignancies. The treatment involves collecting a patient's T cells, genetically modifying them to recognize cancer cells, expanding the cells and then returning them to the patient as a personalized cancer treatment.

Price

Price on Request

Why Price on Request?

The cost depends on patient eligibility, cancer type, cellular therapy product, cell collection, laboratory processing, conditioning treatment, hospitalization and follow-up care. A personalized estimate is provided after clinical evaluation.

Complete Description

What Is CAR T-Cell Therapy?

CAR T-cell therapy is a form of personalized cellular immunotherapy.

A patient's own T cells are collected and modified in a laboratory so they can recognize specific targets on cancer cells. The modified cells are then expanded and administered back to the patient.

Who May Be Eligible for CAR T-Cell Therapy?

CAR T-cell therapy is used for selected patients with specific cancers, particularly certain blood cancers.

Eligibility depends on:

• Cancer type

• Disease stage

• Previous treatments

• Treatment response

• Overall health

• Specific eligibility criteria for the cellular therapy

Not every cancer patient is eligible.

CAR T-Cell Therapy Consultation

The specialist team may review:

• Cancer diagnosis

• Pathology

• Previous treatments

• Imaging

• Laboratory results

• Disease response

• Overall health

The team then determines whether CAR T-cell therapy may be appropriate.

Step 1: Patient Evaluation

Before treatment, patients undergo detailed evaluation to assess:

• Disease status

• Organ function

• Blood counts

• Infection risks

• Previous treatments

• Overall treatment suitability

Step 2: T-Cell Collection

The patient's T cells are collected from the blood through a process called leukapheresis.

The collected cells are then prepared for manufacturing.

Step 3: CAR T-Cell Manufacturing

In a specialized laboratory, T cells are genetically modified to express a chimeric antigen receptor (CAR).

This receptor helps the cells recognize a specific target on cancer cells.

Step 4: Cell Expansion

The modified T cells are multiplied to produce an appropriate number of therapeutic cells.

The final cellular therapy product undergoes quality and safety testing before administration.

Step 5: Conditioning Treatment

Before CAR T-cell infusion, selected patients receive lymphodepleting chemotherapy.

This prepares the body for the CAR T-cell treatment.

Step 6: CAR T-Cell Infusion

The manufactured CAR T cells are returned to the patient through an infusion.

The treatment is personalized because the cells originate from the patient's own immune system.

Step 7: Close Monitoring

Patients require careful monitoring after infusion for potential treatment-related complications.

Monitoring may include:

• Vital signs

• Blood tests

• Neurological assessment

• Infection monitoring

• Inflammatory complications

• Other clinical assessments

Cytokine Release Syndrome

One important potential complication is cytokine release syndrome (CRS).

Symptoms can include:

• Fever

• Low blood pressure

• Rapid heart rate

• Breathing difficulties

• Other systemic inflammatory effects

Patients receiving CAR T-cell therapy are closely monitored for these complications.

Neurological Side Effects

CAR T-cell therapy can also cause neurological complications in some patients.

Possible symptoms may include:

• Confusion

• Difficulty speaking

• Tremors

• Changes in alertness

• Other neurological symptoms

Specialized monitoring is used to identify and manage these effects.

Infection Monitoring

Because CAR T-cell therapy can affect the immune system, patients may require monitoring and supportive care for infection risk.

Blood Count Monitoring

Patients may experience changes in blood-cell counts following treatment.

The care team may monitor:

• Red blood cells

• White blood cells

• Platelets

CAR T-Cell Therapy for Relapsed or Refractory Cancer

CAR T-cell therapy may be considered for selected patients whose cancer:

• Has returned after previous treatment

• Has not responded adequately to previous treatment

• Meets specific eligibility requirements

Multidisciplinary Cellular Therapy Care

CAR T-cell treatment may involve:

• Hematologists

• Medical oncologists

• Cellular therapy specialists

• Laboratory specialists

• Neurology specialists

• Critical-care specialists

• Specialized nursing teams

Follow-Up After CAR T-Cell Therapy

Long-term follow-up may include:

• Cancer response assessment

• Blood tests

• Immune-system monitoring

• Infection monitoring

• Neurological assessment

• Imaging when appropriate

Clinical Trials

Eligible patients may have access to clinical trials investigating:

• New CAR T-cell products

• Next-generation cellular therapies

• CAR T-cell combinations

• Other cellular immunotherapies

CAR T-Cell Therapy Second Opinion

Patients may seek a CAR T-cell therapy second opinion regarding:

• Eligibility

• Previous treatment history

• Alternative cellular therapies

• Clinical trials

• Treatment timing

International Patients

International patients should provide comprehensive oncology records whenever possible.

Useful documents may include:

• Pathology reports

• Biopsy results

• Cancer staging information

• Previous chemotherapy records

• Immunotherapy records

• Radiation records

• CT/MRI/PET reports

• Laboratory results

• Medication list

Benefits of Specialized CAR T-Cell Care

Specialized cellular therapy may provide eligible patients with:

• Personalized cancer treatment

• Advanced cellular immunotherapy

• Specialized eligibility assessment

• Multidisciplinary monitoring

• Access to cellular therapy expertise

• Potential clinical trial opportunities

Why Choose Massachusetts General Hospital for CAR T-Cell Therapy?

Massachusetts General Hospital provides advanced cancer and cellular therapy services through Mass General Cancer Center, with specialized teams involved in cancer evaluation, cellular therapy, treatment administration and follow-up.

Cost & Price on Request

Price: Price on Request

Potential costs may include:

• Cellular therapy consultation

• Eligibility testing

• Leukapheresis

• CAR T-cell manufacturing

• Conditioning chemotherapy

• CAR T-cell infusion

• Hospitalization

• Laboratory monitoring

• Management of treatment-related complications

• Follow-up care

A personalized cost estimate should be requested after eligibility and treatment requirements are determined.

Frequently Asked Questions

1. What is CAR T-cell therapy?

CAR T-cell therapy is a personalized cellular immunotherapy in which a patient's T cells are modified to recognize and attack cancer cells.

2. Is CAR T-cell therapy available for all cancers?

No. It is currently used for selected cancers and eligible patients, particularly certain blood cancers.

3. How are the patient's cells collected?

T cells are collected from the patient's blood through leukapheresis and then sent for specialized processing.

4. Does CAR T-cell therapy require hospitalization?

Some patients require close inpatient monitoring, while care arrangements depend on the specific treatment, patient condition and clinical protocol.

5. How much does CAR T-cell therapy cost?

Price is available on request. Costs can include cell collection, manufacturing, conditioning treatment, infusion, hospitalization and follow-up care.

Product Details

Product Name: CAR T-Cell Therapy at Massachusetts General Hospital

Hospital: Massachusetts General Hospital

Brand: Massachusetts General Hospital

Country: United States

Specialty: Oncology & Cancer Care

Service Type: CAR T-Cell Therapy

Customer-Facing Price: Price on Request

International Patients: Available

Location: Boston, Massachusetts, USA